dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | de la Cruz-Merino, Luis |
dc.contributor.author | Gion, María |
dc.contributor.author | Cruz Jurado, Josefina |
dc.contributor.author | Quiroga, Vanesa |
dc.contributor.author | Andrés, Raquel |
dc.contributor.author | Moreno, Fernando |
dc.contributor.author | Cortés Castan, Javier |
dc.date.accessioned | 2022-06-03T06:54:25Z |
dc.date.available | 2022-06-03T06:54:25Z |
dc.date.issued | 2021-10-29 |
dc.identifier.citation | Cruz-Merino L de la, Gion M, Cruz-Jurado J, Quiroga V, Andrés R, Moreno F, et al. Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study. Cancers. 2021 Oct 29;13(21):5432. |
dc.identifier.issn | 2072-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/7621 |
dc.description | Biomarcadors; Càncer de mama; Pembrolizumab |
dc.description.sponsorship | The study was partially supported by a research grant from Merck’s (MSD in Europe) Investigator Initiated Studies Program, which also supplied the pembrolizumab. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cancers;13(21) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Immunoteràpia |
dc.subject | Mama - Càncer - Tractament |
dc.subject.mesh | Triple Negative Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Immunotherapy |
dc.title | Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cancers13215432 |
dc.subject.decs | neoplasias de mama triple negativos |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | inmunoterapia |
dc.relation.publishversion | https://doi.org/10.3390/cancers13215432 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [de la Cruz-Merino L] Medical Oncology Department, Virgen Macarena University Hospital, Medicine Department University of Seville, Seville, Spain. GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. [Gion M] GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Cruz-Jurado J] GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. [Quiroga V] GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. Medical Oncology Department, Badalona Applied Research Group in Oncology (B-ARGO Group), Catalan Institute of Oncology, Badalona, Spain. [Andrés R] GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. Medical Oncology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. [Moreno F] GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. Medical Oncology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain. [Cortés J] GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. International Breast Cancer Center (IBCC), Quirón Teknon Hospital (Quironsalud Group), Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain |
dc.identifier.pmid | 34771596 |
dc.identifier.wos | 000719460800001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |